Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.

Cancer medicine - 1 Jan 2022

Balasubramanian Sriram, Hodkinson Brendan, Schuster Stephen J, Fowler Nathan H, Trotman Judith, Hess Georg, Cheson Bruce D, Schaffer Michael, Sun Steven, Deshpande Sanjay, Vermeulen Jessica, Salles Gilles, Gopal Ajay K

Abstract excerpt

BACKGROUND: The single-arm DAWN trial (NCT01779791) of ibrutinib monotherapy in patients with relapsed/refractory follicular lymphoma (FL) showed an overall response rate (ORR) of 20.9% and a median response duration of 19.4 months. This biomarker analysis of the DAWN dataset sought to determine genetic classifiers for prediction of response to ibrutinib treatment. METHODS: Whole exome sequencing was performed on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CARD Signaling Adaptor Proteins

Share to Exome Sequencing

Share to Guanylate Cyclase

Share to Lymphoma, Follicular

Share to Piperidines

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 34791836
DOI: 10.1002/cam4.4422
PMCID: PMC8704158

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.PMID 34791836Read ↗

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.Semantic proximity Read ↗

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.Semantic proximity Read ↗

Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.Semantic proximity Read ↗

Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors.Semantic proximity Read ↗

Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus BendamustineSemantic proximity Read ↗

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.Semantic proximity Read ↗

Identification of genetic subtypes in follicular lymphoma.Semantic proximity Read ↗

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.Semantic proximity Read ↗

Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.Semantic proximity Read ↗

The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs.Semantic proximity Read ↗

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.